NL-OMON36896已完成不适用
A Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX507-H in Healthy Male and Female Subjects - CCX507-H SAD/FE study
Chemocentryx0 个研究点目标入组 31 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male and female
- •19-65 years inclusive
- •BMI 18.5 - 30.0 inclusive
- •non-smoker
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS.
- •Participation in another drug study within 60 days prior to randomization.
- •Any donation of blood(products) or significant blood loss within 56 dagen prior to screening.
研究者
相似试验
已完成
不适用
A double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetic properties of TV-1380 in healthy volunteers.NL-OMON34473TEVA Pharma56
已完成
不适用
A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects with Established Parkinson*s DiseasePDParkinson's diseaseNL-OMON48411Alexza Pharmaceuticals Inc.32
进行中（未招募）
1 期
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 YearsDengue FeverEUCTR2022-003455-33-Outside-EU/EEATakeda Vaccines, Inc.
已完成
不适用
A Phase 1 Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nipocalimab in Healthy Male and Female Participants.NL-OMON50999Janssen-Cilag60
已完成
不适用
A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX872-B in Healthy Male and Female SubjectsNephropathynierfalen10029149NL-OMON37040Chemocentryx40